Aura Biosciences reports FY2021 net loss $35.3M; cash $149.1M into 2024

Aura Biosciences, Inc.

Net loss for FY2021 was $35.3M, up from $22.2M in FY2020; R&D expenses rose to $25.2M.
Cash and equivalents totaled $149.1M at Dec 31, 2021; runway into 2024.
On track to initiate pivotal trial in choroidal melanoma and Phase 1 in NMIBC in 2H 2022.
European Commission granted Orphan Drug Designation for AU-011 in uveal melanoma.
John Maraganore, former Alnylam CEO, joins as strategic advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.